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Abstract
Respiratory syncytial virus (RSV) is an important cause of acute respiratory disease in infants, immunocompromised subjects
and the elderly. However, it is unclear why most primary RSV infections are associated with relatively mild symptoms,
whereas some result in severe lower respiratory tract infections and bronchiolitis. Since RSV hospitalization has been
associated with respiratory bacterial co-infections, we have tested if bacterial Toll-like receptor (TLR) agonists influence RSV-
A2-GFP infection in human primary cells or cell lines. The synthetic bacterial lipopeptide Pam3-Cys-Ser-Lys4 (Pam3CSK4), the
prototype ligand for the heterodimeric TLR1/TLR2 complex, enhanced RSV infection in primary epithelial, myeloid and
lymphoid cells. Surprisingly, enhancement was optimal when lipopeptides and virus were added simultaneously, whereas
addition of Pam3CSK4 immediately after infection had no effect. We have identified two structurally related lipopeptides
without TLR-signaling capacity that also modulate RSV infection, whereas Pam3CSK4-reminiscent TLR1/2 agonists did not,
and conclude that modulation of infection is independent of TLR activation. A similar TLR-independent enhancement of
infection could also be demonstrated for wild-type RSV strains, and for HIV-1, measles virus and human metapneumovirus.
We show that the effect of Pam3CSK4 is primarily mediated by enhanced binding of RSV to its target cells. The N-
palmitoylated cysteine and the cationic lysines were identified as pivotal for enhanced virus binding. Surprisingly, we
observed inhibition of RSV infection in immortalized epithelial cell lines, which was shown to be related to interactions
between Pam3CSK4 and negatively charged glycosaminoglycans on these cells, which are known targets for binding of
laboratory-adapted but not wild-type RSV. These data suggest a potential role for bacterial lipopeptides in enhanced
binding of RSV and other viruses to their target cells, thus affecting viral entry or spread independent of TLR signaling.
Moreover, our results also suggest a potential application for these synthetic lipopeptides as adjuvants for live-attenuated
viral vaccines.
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Introduction
Human respiratory syncytial virus (RSV) is a major cause of
respiratory tract disease in infants, immunocompromised subjects
and the elderly [1]. The virus is a member of the family
Paramyxoviridae, which also includes human metapneumovirus
(HMPV) and measles virus (MV). RSV owes its name to the
formation of multinucleated syncytia within infected epithelial cells
of the respiratory tract [2–4]. RSV shows a seasonal epidemiology
associated with worldwide peaks in virus transmission during the
winter or rainy season [5]. In most cases the virus causes a mild
and self-limiting upper respiratory tract infection. However, in
some cases (usually estimated as 1–2%) the virus spreads to the
lower respiratory tract, and may cause severe bronchiolitis or
pneumonia [1,5]. A substantial proportion of these patients
require hospitalization, and occasionally mechanical ventilation.
Risk factors for developing severe RSV disease include
premature birth, immune deficiency, underlying chronic lung
disease or congenital heart disease [1,5]. However, in the majority
of hospitalized cases no risk factor can be identified. The
pathogenesis of these severe RSV cases remains poorly under-
stood. Different explanations have been proposed, such as
anatomical predispositions, mucus overproduction, skewed T-
helper 2 immune responses or co-infections. Some studies have
suggested that co-infections by RSV and the closely related
HMPV may result in severe disease [6,7], but co-infections with
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especially for Streptococcus pneumoniae (SP) [8–11]. Invasive pneu-
mococcal disease has been shown to be more prevalent during the
RSV season [12]. In addition, the frequency of hospitalization for
severe RSV disease is reduced in children who have been
vaccinated against SP [13].
In addition to SP, different bacteria have been detected in nasal
swabs, nasopharyngeal aspirates or broncho-alveolar lavages of
children with severe RSV infections, including Staphylococcus aureus
(SA), Haemophilus influenza (HI) and Moraxella catarrhalis (MC). RSV-
infected children are often co-diagnosed with otitis media caused
by SP, HI or MC [14]. It is often assumed that viral infections
precede superinfection with bacteria [15–17], by causing epithelial
damage that allows bacterial colonization or by facilitating
bacterial binding to epithelial cells [18–20]. However, an inverse
order of events cannot be excluded: respiratory bacteria may
facilitate virus infections by activating target cells or modulating
virus-specific immune responses [21].
The mammalian immune system has developed pattern recogni-
tion molecules such as Toll-like receptors (TLRs) [22], which are not
only expressed by professional antigen-presenting cells but also by
epithelial cells of the respiratory tract [23–25]. TLR triggering by
pathogens, including bacterial structures, leads to an innate and
adaptive immune response to specifically combat the invading
pathogen. However, by changing the phenotype of the cell, TLR
signaling might also increase the susceptibility of cells to virus
infection. For HIV-1 it has been described that bacterial TLR ligands
enhance infection of and transmission to target cells [26–30]. Here,
we have examined the effect of bacterial TLR ligands and structurally
related molecules on RSV infection in different cell types.
Results
The lipopeptide and prototype TLR1/2 agonist
Pam3CSK4 modulates RSV infection of epithelial and
antigen presenting cells
The TLR family consists of more than ten members, each
interacting with specific pathogenic structures [31]. TLR1, 2, 4, 5
and 6 have been shown to interact with bacterial structures. A
panel of prototype bacterial TLR ligands was tested for their
ability to modulate RSV infection of different target cells. Both
primary cells and immortalized cell lines were used, since TLR
expression is influenced by the activation status of cells. The
epithelial cells, the main target cells for RSV infection, were the
initial focus of our investigation. Following a previously described
protocol [28], cells were pre-incubated with the respective TLR
ligands and subsequently infected with a recombinant RSV (strain
A2) that encodes enhanced GFP (rgRSV) [32]. In primary
undifferentiated normal human bronchial epithelial (NHBE) cells,
pre-incubation with the synthetic bacterial lipopeptide Pam3-Cys-
Ser-Lys4 (Pam3CSK4) enhanced rgRSV infection (p,0.05),
whereas the other TLR ligands did not modulate infection
(Figure 1A). Pam3CSK4 was also found to enhance rgRSV
infection in well-differentiated NHBE cells grown on air-liquid
interface (results not shown). The epithelial cell lines A549 and
HEp-2 are frequently used to study RSV infection and the
percentage of infected cells is higher compared to the primary
NHBE cells (Figure 1A). Surprisingly, and in contrast to NHBE
cells, Pam3CSK4 and to a lesser extent Pam2CSK4 did not
enhance but rather decreased rgRSV infection in A549 and HEp-
2( p ,0.05) (Figure 1B, C).
Antigen presenting cells (APC) in the respiratory tract, such as
alveolar macrophages and dendritic cells, are exposed to RSV
during infection. The level of infection of these cells in vivo and the
contribution of these cells to RSV pathogenesis is currently
unknown. Since APC are highly responsive to TLR agonists, we
studied infection of primary antigen presenting cells, including
monocyte-derived dendritic cells and BAL cells, in the presence
and absence of TLR agonists. In addition, we also used an
Epstein-Barr virus-transformed B-lymphoblastic cell line (B-LCL)
representing RSV infection of lymphoid APC. APC can be
infected with RSV but are relatively resistant compared to
epithelial cells. Using a 5-fold higher dose in immature
monocyte-derived dendritic cells (DCs) (Figure 1D) and a 10-fold
higher dose in BAL cells and B-LCL (Figure 1E,F), infection with
rgRSV resulted in 2%, 1%, and 5% GFP-expressing cells,
respectively. Similar to NHBE cells, pre-incubation of APC with
Pam3CSK4 strongly increased rgRSV infection levels in these cells
(p,0.05) (Figure 1D-F). These results demonstrate that the
TLR1/TLR2 ligand Pam3CSK4 modulates rgRSV infection of
different target cells.
Pam3CSK4-mediated enhancement of RSV infection in
APC is a rapid and dose-dependent process
To further investigate the mechanism by which Pam3CSK4
enhances RSV infection, the optimal time for addition of the
lipopeptide before or after infection was determined. For these
studies B-LCL were used, as these are easier to work with than the
primary epithelial cells or myeloid APC and thus facilitated further
experiments. At different time points before or after infection with
rgRSV B-LCL were incubated with Pam3CSK4. Interestingly,
addition of the lipopeptides at the same time as the virus resulted
in the highest percentages of infected cells (p,0.005, Figure 2A).
This result suggests that Pam3CSK4 directly influences binding or
entry of the virus. A similar enhancement of rgRSV infection
could also be demonstrated using alternative readout parameters,
including measurement of virus titers in supernatant by endpoint
titration or assessment of numbers of infected cells by infectious
centre assay (data not shown).
Subsequently, RSV or B-LCL were pre-incubated with different
concentrations of Pam3CSK4 for 30 min at 37uC before infection
and overnight culture. A convincing and dose-dependent en-
Author Summary
Respiratory syncytial virus (RSV) infections are an impor-
tant cause of hospitalization of infants during the winter
season. However, RSV is often not the only detectable
pathogen, but co-infections with respiratory bacteria are
common. It has been hypothesized that this results from
epithelial damage caused by the virus, facilitating coloni-
zation by pathogenic bacteria such as Streptococcus
pneumoniae. However, an inverse order of events is not
impossible: bacterial infections may activate respiratory
epithelial cells through TLR signaling, resulting in in-
creased susceptibility to virus infections. We tested this
hypothesis by screening bacterial TLR agonists for their
capacity to modulate RSV infection in different cell types,
and identified the lipopeptide and prototype TLR1/2
agonist Pam3CSK4 as an enhancer of RSV infections.
However, to our surprise this proved independent of TLR
activation, but was mediated by enhancement of binding
between virus and target cell. Two structurally related
lipopeptides unable to stimulate TLR responses were
identified that enhanced infections with RSV, but also
with other enveloped viruses including HIV-1, human
metapneumovirus, and measles virus. We speculate that
bacterial infections may influence the pathogenesis of
virus infections by facilitating binding to target cells.
Lipopeptide-Mediated Enhancement of Virus Binding
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Figure 2B). At 30 mg/ml Pam3CSK4 became toxic for the cells,
resulting in a declining percentage of infected cells especially in the
condition where cells had been exposed directly. To discriminate
between pre- and post-entry mechanisms, B-LCL were incubated
with different concentrations of Pam3CSK4 directly before or
after rgRSV infection. In B-LCL incubated with Pam3CSK4 and
washed before rgRSV infection, enhancement of infection was still
detectable (p,0.01, Figure 2C), suggesting that cell-bound
Pam3CSK4 directly or indirectly increased rgRSV infection. In
contrast, Pam3CSK4 did not influence the percentage of GFP-
expressing cells when the lipopeptide was added immediately after
rgRSV infection and subsequent washing to remove unbound
virus, suggesting that Pam3CSK4 does not affect post-binding or -
entry steps of RSV infection, such as transcription, replication,
release and second round infection. In addition, as Pam3CSK4
was washed away the toxic effect was not present anymore,
resulting in enhancement for all tested concentrations. Moreover,
the level of GFP expression in Pam3CSK4-stimulated cells was
similar to GFP expression in untreated cells, suggesting that RSV
transcription was not influenced (data not shown). In order to
exclude that the observed effect was related to a specific property
of the recombinant RSV strain used in these experiments, we also
tested the effect of Pam3CSK4 on infection of B-LCL with
different laboratory or wild-type strains of RSV, which resulted in
a similar enhancement of infection (p,0.05, Figure 2D). Thus, we
conclude that Pam3CSK4 enhances RSV binding or entry in B-
LCL. These findings were corroborated in primary epithelial cells
and DCs (data not shown).
Pam3CSK4 enhances RSV binding to target cells
independent of TLR signaling
Since the addition of Pam3CSK4 together with RSV had the
largest influence on rgRSV infection, we hypothesized that TLR
triggering and subsequent phenotypical changes might not be
involved in this effect. Indeed, neither blocking of Pam3CSK4
binding to TLR by neutralizing antibodies nor blocking of TLR
signaling by blocking peptides abrogated enhancement of rgRSV
infection by Pam3CSK4 (p,0.05, Figure 3A). To further support
these results, different lipopeptides were used that were structurally
similar to Pam3CSK4 but do not contain TLR signaling capacities
(see Figure S1 for molecular structures). Pam-Cys-SK4 and
PHCSK4 do not induce TLR signaling [33,34], but enhanced
rgRSV infection in B-LCL (p,0.05, Figure 3B). Furthermore,
Pam3CSP4, which is equally effective in inducing TLR responses
as Pam3CSK4 [35], did not enhance rgRSV infection under these
conditions (Figure 3B). Thus, Pam3CSK4 enhances RSV infection
independently of TLR signaling.
To investigate whether Pam3CSK4, Pam-Cys-SK4 and
PHCSK4 enhance attachment of rgRSV to target cells, an RSV
binding assay was performed. In contrast to Pam3CSP4, pre-
Figure 1. Pam3CSK4 modulates rgRSV infection in different cell types. (A–F) Primary cells or immortalized cell-lines were incubated with
bacterial TLR ligands using conditions as described previously [28]. In undifferentiated primary normal human bronchial epithelial (NHBE) cells,
antigen presenting cells (immature DC, BAL cells and EBV-transformed B-LCL), Pam3CSK4 mediated significant enhancement of rgRSV infection
(*p,0.05 in 1-way ANOVA and posthoc Dunnett’s correction for multiple comparisons with medium control). In contrast, treatment of A549 or HEp-2
cells with Pam3CSK4 and Pam2CSK4 resulted in reduced rgRSV infection levels (*p,0.05 using Dunnett’s correction). Data are presented as
percentages GFP-positive cells (means 6 SD of triplicates). A representative experiment out of three is shown.
doi:10.1371/journal.ppat.1001049.g001
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PHCSK4 increased binding to B-LCL (p,0.05, Figure 3C).
Subsequently, the direct interaction of lipopeptides and viruses was
investigated in an RSV binding ELISA. The different lipopeptides
were coated onto ELISA plates and subsequently incubated with
rgRSV. Pam3CSK4, Pam-Cys-SK4 and PHCSK4, but not
Pam3CSP4, were found to bind rgRSV (p,0.05, Figure 3D).
Finally, B-LCL were incubated with the fluorescent (lipo)peptides
Pam3CSK4-CF or CSK4-CF at 4uCo r3 7 uC, demonstrating
effective membrane binding of Pam3CSK4-CF at concentrations
that were also found to enhance rgRSV infection (p,0.01,
Figure 3E). Together these results demonstrate that Pam3CSK4
interacts directly with rgRSV or its target cells, enhances binding
of rgRSV to target cells and thereby increases infection efficiency,
all independent of TLR signaling.
Charge and structure of lipopeptides play an essential
role for enhancement
Charge and structure can play important roles in molecular
interactions. Several cationic molecules have been described to
enhance viral infections [36–38]. To determine the role of
the four lysines in Pam3CSK4, which are strongly cationic,
Figure 2. Pam3CSK4 mediates rapid and dose-dependent enhancement of RSV infection in B-LCL. (A) B-LCL were incubated at 37uC
with Pam3CSK4 (10 mg/ml) at 6 h, 3 h, 1.5 h, 0.5 h or 0 h before or 0.5 h, 1.5 h, 3 h, and 6 h after rgRSV infection. Pam3CSK4 treatment resulted in
significantly increased rgRSV infection percentages in B-LCL at all time points (*p,0.005 with Student’s t-tests with Bonferroni correction for multiple
comparisons). (B) B-LCL or virus were pre-incubated with different concentrations of Pam3CSK4 for 30 minutes at 37uC before infection with rgRSV.
Pam3CSK4 treatment resulted in significantly increased rgRSV infection percentages (p,0.05 for Pam3CSK4 concentrations $3 mg/ml), but no
biologically relevant differences were detected between pre-incubation of cells or virus. (C) Cells were treated with different concentrations of
Pam3CSK4 either directly before or after rgRSV infection. In all conditions free lipopeptide or free virus was washed away before proceeding to the
next step. Pam3CSK4 treatment resulted in significantly higher percentages of infected cells (p,0.01, significant under Bonferroni correction for
Pam3CSK4 concentrations $3 mg/ml). However, addition of Pam3CSK4 after rgRSV infection and subsequent removal of free virus had no effect. (D)
B-LCL were incubated for 30 minutes at 37uC with or without Pam3CSK4 (10 mg/ml) before infection with different RSV strains. Pam3CSK4 treatment
resulted in increased RSV infection percentages (p,0.05) for all strains tested. In all panels data are presented as percentages RSV-infected cells
(means 6 SD of triplicates) 20–24 hours after infection as determined by flow cytometry, using GFP expression in panels A–C and staining with FITC-
labeled RSV-specific antibodies in panel D. Representative experiments out of three are shown.
doi:10.1371/journal.ppat.1001049.g002
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PLoS Pathogens | www.plospathogens.org 4 August 2010 | Volume 6 | Issue 8 | e1001049Figure 3. The effect of Pam3CSK4 on B-LCL is independent of TLR signaling, but mediated by enhanced virus binding. (A) B-LCL were
pre-incubated with the myeloid differentiating factor 88 (MyD88) homodimerization inhibitory peptide, a control peptide, or polyclonal blocking
antibodies to TLR1, TLR2 and/or TLR4, followed by Pam3CSK4 incubation (10 mg/ml, 30 minutes, 37uC) and subsequent infection with rgRSV. In all
conditions Pam3CSK4 treatment resulted in enhancement of rgRSV infection (p,0.05). (B) B-LCL were incubated with different lipopeptides (for
molecular structures see Figure S1) with or without TLR signaling capacities. In addition to TLR agonist Pam3CSK4 two non-TLR2 activating
lipopeptides Pam-Cys-SK4 and PHCSK4 enhanced rgRSV infection, whereas the TLR agonist Pam3CSP4 did not (p,0.05 with Dunnett’s correction for
Lipopeptide-Mediated Enhancement of Virus Binding
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(Pam3CSP4), the weakly cationic histidine (Pam3CSH4), the
strongly cationic arginine (Pam3CSR4), or the negatively charged
glutamic acid (Pam3CSE4) (see Figure S1 for molecular
structures). Of these lipopeptides, only Pam3CSK4 was able to
enhance rgRSV infection (Figure 4A). Despite their positive
charge, neither Pam3CSH4 nor Pam3CSR4 were capable of
enhancing RSV infection. In contrast to the other four lipo-
peptides, Pam3CSE4 reproducibly inhibited RSV infection
(p,0.05).
multiple comparisons for Pam3CSK4, Pam-Cys-SK4, and PHCSK4 concentrations 3 and 10 mg/ml). (C) RSV binding to B-LCL was determined by pre-
incubating rgRSV with the different lipopeptides, followed by assessment of binding to cells. RSV binding was quantified by staining with FITC-
labeled antibodies to RSV or to influenza-B as a control. Addition of the lipopeptides Pam3CSK4, Pam-Cys-SK4 and PHCSK4 but not Pam3CSP4
significantly increased binding of RSV to the cells (p,0.05 using Dunnett’s correction for multiple testing). (D) Direct RSV binding to lipopeptides was
examined in an ELISA format. Lipopeptides were coated on high-binding ELISA plates and incubated with RSV, or with MV strain Edmonston as a
control. RSV binding was measured using an RSV-specific monoclonal antibody, followed by detection using a goat-anti-mouse peroxidase and TMB
as a substrate. Coating with Pam3CSK4, Pam-Cys-SK4 and PHCSK4 but not with Pam3CSP4 resulted in increased RSV binding (p,0.05 compared with
Dunnett’s correction). Data are shown as extinctions at 450 nm (means 6 SD of duplicates). (E) B-LCL were incubated with Pam3CSK4-CF or CSK4-CF
at 4uCo r3 7 uC to measure direct (lipo)peptide binding to the cells. At both temperatures Pam3CSK4-CF showed significantly stronger binding than
CSK4-CF (p,0.01 with Bonferroni correction at concentrations 10 and 30 m/ml). In panels A-C results are shown as percentages GFP- or FITC-positive
cells (means 6 SD of duplicates) and in Panel E data are shown as geometric mean fluorescence (means 6 SD of triplicates). Representative examples
of at least three experiments are shown.
doi:10.1371/journal.ppat.1001049.g003
Figure 4. Importance of lipopeptide charge and structure. (A, C, D) B-LCL were incubated with different lipopeptides for 30 minutes at 37uC
before infection with rgRSV. Only Pam3CSK4, Pam-Cys-SK4, Pam3CSK2 and Pam3CSK5 resulted in enhancement of rgRSV infection, whereas
Pam3CSE4 resulted in inhibition of rgRSV infection compared to medium control (p,0.05 in 1-way ANOVA and posthoc Dunnett’s correction). (B)
Natural and chemically-derived polyanionic compounds were assessed to block the Pam3CSK4-mediated enhancement of RSV infection. The
compounds were added to cells that had been pre-incubated with Pam3CSK4 or Pam3CSP4 as a control, followed by infection with RSV. The next day
percentages GFP-expressing cells were determined by flow cytometry. The strongly polyanionic compounds heparin, dextran sulfate, over-sulfated
heparin and over-sulfated chondroitin sulfate were able to abrogate the Pam3CSK4-mediated enhancement of rgRSV infection (p,0.05 using
posthoc Dunnett’s correction), whereas the control compounds chondroitin sulfate and de-sulfated heparin had only a minimal effect or no effect,
respectively. Error bars represent the standard deviation of triplicates. A representative experiment out of three is shown.
doi:10.1371/journal.ppat.1001049.g004
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Pam3CSK4 and cells or virus, various polyanionic compounds
were tested to shield the positive charge of Pam3CSK4, using
previously described conditions [38]. Two naturally occurring
polyanionic compounds, heparin and chondroitin sulfate, and four
chemically desulfated or oversulfated anionic polymers, dextran
sulfate, over-sulfated heparin, de-sulfated heparin and oversulfated
chondroitin sulfate, were tested for their effect on the interaction
between Pam3CSK4 and RSV. Desulfated or oversulfated anionic
polymers were used to normalize for differences in relative anionic
strengths between the naturally existing compounds. After
incubation of B-LCL with Pam3CSK4, heparin, dextran sulfate,
or chondroitin sulfate were added, resulting in a decreased levels of
rgRSV infection after treatment with heparin and dextran sulfate
(p,0.05), whereas chondroitin sulfate did not effectively block
rgRSV infection (Figure 4B). Oversulfated heparin and over-
sulfated chondroitin sulfate inhibited Pam3CSK4-mediated en-
hancement of RSV infection (p,0.05), but desulfated heparin did
not. In addition, RSV binding experiments using B-LCL
incubated with Pam3CSK4 showed decreased virus binding after
treatment with heparin, dextran sulfate, oversulfated heparin or
over-sulfated chondroitin sulfate, but not after treatment with
chondroitin sulfate or de-sulfated heparin (data not shown). These
results suggest that highly sulfated polyanions neutralize the
cationic property of the cell-bound Pam3CSK4, resulting in
abrogation of the Pam3CSK4-mediated enhancement of RSV
binding and infection, and confirm that cationic properties of
Pam3CSK4 are crucial for their capacity to enhance RSV
infections.
Subsequently, other properties of the lipopeptide structure were
studied. Two lipopeptides with either one (Pam-Cys-SK4), two
(Pam2CSK4) or three (Pam3CSK4) palmitoyl residues were tested
for their capacity to enhance rgRSV infection in B-LCL (see
Figure S1 for molecular structures). Pam-Cys-SK4 strongly
enhanced rgRSV infection (p,0.05), whereas Pam2CSK4 had
limited to no enhancing properties, demonstrating that the amino-
linked palmitoyl group is crucial for the enhancing properties
(Figure 4C). In addition, a Pam-Cys-SK4-reminiscent lipopeptide,
containing the prokaryotic amino acid S-(2,3-dihydroxypropyl)-
cysteine (Dhc) characterized by two free hydroxyl groups
(PamDhcSK4), and a lipopeptide completely lacking the cysteinyl
partial structure (PamSK4) were tested, which both were unable to
enhance infection. These results demonstrated that the amphi-
philic feature and cationic lysins per se are insufficient for
enhancement, and strongly suggest that the N-palmitoylated
cysteine is necessary as membrane anchor. Evaluation of
Pam3CSK4-reminiscent lipopeptides with two or five instead of
four lysins (Pam3CSK2 and Pam3CSK5, respectively) showed
that all could enhance rgRSV infection in B-LCL (p,0.05, see
Figure S1 for molecular structures). However, the level of
enhancement was not simply related to the number of cationic
lysins in the lipopeptide, as Pam3CSK2 showed a stronger
enhancement than Pam3CSK5 (Figure 4D).
Pam3CSK4, Pam-Cys-SK4 and PHCSK4 also enhance
infection with other enveloped viruses
Previously, it has been described that Pam3CSK4 enhances
infection with or transmission of HIV-1 [28–30]. Here we show
that the non-TLR agonists Pam-Cys-SK4 and PHCSK4 are
equally capable of enhancing HIV-1 infection of a Jurkat-CCR5
cells as Pam3CSK4 (p,0.05, Figure 5A), indicating that also for
HIV-1 TLR signaling-independent enhancement of infection can
be observed. The same could be shown for two viruses from the
same family as RSV: HMPV and two different MV strains
(p,0.05, Figure 5B–D). For MV we also performed a virus
binding assay and were able to show that, similar as described
above for RSV, the enhancement was indeed mediated by
enhancement of MV binding to their target cells (Figure S2).
These viruses share membrane fusion as a common entry
mechanism [39], but contain different attachment proteins and
target different cellular receptors, suggesting that enhancement of
virus binding is based on interactions between lipopeptides and
biomembranes or common membrane-associated structures rather
than with specific cellular or viral proteins.
Interactions between cationic lipopeptides and GAGs
explain inhibition of RSV infection in A549 and HEp-2
cells
As described above and shown in Figure 1, and in sharp
contrast to the reproducible enhancement of RSV infection in
undifferentiated NHBE cells, BAL cells, dendritic cells and B-
LCL, Pam3CSK4 inhibited RSV infection in the epithelial cell
lines A549 and HEp-2. An important difference between these cell
lines and the other cell types used in this study is the high
expression level of GAGs in the immortalized epithelial cell lines
A549 and HEp-2. GAGs are negatively charged long unbranched
polysaccharides associated with proteoglycans (chondroitin-,
dermatan-, heparan- and keratansulfate) expressed on cell
membranes. It has been described that rgRSV and other
laboratory-adapted RSV strains can use GAGs as cellular
receptor, although this is considered an in vitro artifact and these
molecules are not used as cellular receptors in vivo [40]. To address
the role of GAGs in the observed Pam3CSK4-mediated inhibition
of rgRSV infection in epithelial cell lines, we used Chinese hamster
ovary cell (CHO) mutants deficient in GAG synthesis [40]. Wild-
type and two GAG-deficient CHO cell lines (CHO-pgsA745
completely deficient in GAGs and CHO-pgsD677 deficient for
heparan sulfate) were tested at the same multiplicity of infection
(MOI) in two conditions. As expected, the percentage of rgRSV
infection in A549 and wild-type CHO in the absence of
lipopeptide was significantly higher than in the mutant CHO
cells (p,0.01). Pre-incubation of cells with Pam3CSK4 decreased
RSV infection levels in A549 and wild-type CHO cells, but
enhanced infection in the GAG-deficient CHO cells (Figure 6). If
the virus was pre-treated with the lipopeptide instead of the cells,
enhancement was observed in all four cell lines (Figure 6). These
findings demonstrate that Pam3CSK4-mediated inhibition of
rgRSV infection in immortalized epithelial cell lines is related to
interactions between the cationic lipopeptides and the negatively
charged GAGs.
Discussion
In the present study we have shown that Pam3CSK4 and at
least two other structurally-related cationic lipopeptides can
enhance infections with RSV, HIV-1, HMPV or MV independent
of TLR signaling. By using rgRSV infection of B-LCL as a model
system, we have shown that these lipopeptides can bind directly to
both cells and virus, and strongly enhance virus binding to target
cells. In contrast, Pam3CSK4 reduced rgRSV infection levels of
A549 and HEp-2 cells under specific conditions, due to
interactions with the negatively charged GAGs expressed on the
surface of these cells.
Pam3CSK4 is a synthetic tripalmitoylated bacterial lipopeptide
and is a potent activator of the NF-kB pathway, by forming an m-
shaped heterodimer of TLR1 and TLR2 [41]. It has been
described that Pam3CSK4 enhances infection or transmission of
HIV-1 in different systems [28–30]. Our data show that
Lipopeptide-Mediated Enhancement of Virus Binding
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HIV-1, but can also be shown for a number of other enveloped
viruses including RSV, HMPV and MV. By blocking either
binding to TLR1/2 or TLR1/2 signaling, and by using enhancing
lipopeptides that do not activate TLR1/2, we demonstrate that
this enhancement of RSV infection is independent of TLR
signaling. Although we cannot exclude a role for TLR stimulation
in HIV-1 transmission by Langerhans cells, our observations in
Jurkat cells that Pam-Cys-SK4 and PHCSK4 showed a similar
enhancement of HIV-1 infection as Pam3CSK4 demonstrate that
also for HIV-1 TLR-signaling-independent enhancement of
infection can be observed, and is likely related to a similar
mechanism as shown for RSV and MV.
Using different lipopeptides we identified the cationic properties
and the N-palmitoylated cysteine in Pam3CSK4 as crucial
characteristics for enhancement of virus infection. We suggest
that the N-palmitoylated cysteine may function as a structure
interacting directly with the viral or target cell membrane. It has
previously been described in the murine B-cell leukemia line BCL1
that already 20 minutes after incubation with Pam3-Cys-Ser a
major amount of the lipopeptide can be found in the plasma
membrane [42]. After membrane binding by Pam3CSK4 the
exposed cationic SK4 sequence could subsequently interact with
negatively charged structures on the membrane of virus or cell,
and result in infection enhancement similar to what has been
described for other cationic agents such as DEAE-dextran,
polybrene or semen-derived enhancer of viral infection (SEVI)
[37,38,43]. Interestingly, we found that highly sulfated polyanions
could abrogate Pam3CSK4-mediated enhancement of rgRSV
infection or binding, in a pattern almost completely identical to
that described for the interaction between these compounds and
SEVI [38]. However, additional non-electrostatic forces may be of
importance, as two other lipopeptides containing positively
charged amino acids, Pam3CSH4 and Pam3CSR4, could not
mediate enhancement of RSV infection.
Pam3CSK4 was found to decrease RSV infection in epithelial
cell lines A549 and HEp-2. However, this effect was only
observed when the cells were pre-incubated with the lipopeptide,
and not when the virus was pre-incubated with the lipopeptide. It
has been described that rgRSV can efficiently bind to GAGs
expressed on immortalized epithelial cell lines [44]. This effect is
generally considered an in vitro artifact, as wild-type RSV strains
Figure 5. Enhancement of infection with other enveloped viruses. (A–D) Jurkat-CCR5 cells (A) or B-LCL (B–D) were incubated with different
lipopeptides (10 mg/ml, Pam3CSK4, Pam-Cys-SK4, PHCSK4, or Pam3CSP4) before infection with HIV-RgBaL-GFP (A), HMPV-EGFP (B), rMV-Edmonston-
EGFP (C) or rMV-IC323-EGFP (D), respectively. Two (HIV-1) or one (HMPV, MV) day later the percentage of GFP-expressing cells was determined by
flow cytometry. In all experiments Pam3CSK4, Pam-Cys-SK4 and PHCSK4 treatment resulted in significantly higher infection percentages (p,0.05
using posthoc Dunnett’s correction for multiple comparisons). Error bars represent the standard deviation of triplicates. A representative experiment
out of three is shown.
doi:10.1371/journal.ppat.1001049.g005
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pre-incubation of A549 cells with the cationic Pam3CSK4 may
reduce virus binding to the negatively charged GAGs, thus
interfering with the normal attachment of RSV to these cells.
Using a GAG-independent virus (MV) we could not detect
reduced infection levels in A549 cells pre-incubated with
Pam3CSK4 (data not shown). In order to test our hypothesis
we performed RSV infections in normal or GAG-deficient CHO
cells and indeed measured inhibition on pre-incubated CHO-
cells expressing GAGs, but not in GAG-deficient CHO-cells.
Since Pam3CSK4 not only enhanced infection of rgRSV but also
of wild-type RSV isolates in B-LCL and primary epithelial cells,
and this lipopeptide also enhanced infections with HIV-1,
HMPV, and MV, we believe that the inhibition of rgRSV
infection in A549 and Hep-2 cells is solely related to the
laboratory adaptation of rgRSV to efficiently bind GAGs, and
does not reflect potential interactions between bacterial lipopep-
tides and wild-type RSV infection in vivo.
Other cationic compounds, such as DEAE-dextran, polybrene,
RANTES, and SEVI, have also been shown to enhance viral
infection [38,43,45]. Polybrene, a synthetic cationic polymer
neutralizing the charge repulsion between the virus and the cell
surface, leads to enhancement of infection of a variety of
retroviruses, including HIV [46]. SEVI enhances HIV infection
by cross-linking HIV viruses to target cells, facilitating subsequent
fusion [38,45]. RANTES, a cationic chemokine, has been reported
to enhance HIV-1 infection by binding to proteoglycans on the
surface of target cells [47]. Interestingly, RANTES has also been
associated with inhibition of RSV infection in HEp2-cells [48],
which could be mediated through an analogous mechanism to
Pam3CSK4-mediated reduction of rgRSV infection in A549 cells
described here.
Pam3CSK4 is a synthetic mimic of the N-terminal parts of
lipopeptides present in the cell walls of gram-positive and gram-
negative bacteria, which have been identified as TLR agonists
[49]. Therefore, the biological property of these lipopeptides as
Figure 6. Mechanism of reduced rgRSV infection of A549 cells in relation to GAG expression. A549, CHO K-1, CHO pgsA-745 or CHO
pgsD-677 cells were infected with rgRSV after pre-incubation of the cells (black symbols) or the virus (white symbols) with Pam3CSK4 (10 mg/ml) for
30 minutes at 37uC. In the GAG-expressing cell lines A549 and CHO-K1 pre-incubation of cells with Pam3CSK4 resulted in reduction of RSV infection,
but in the GAG-deficient cell lines CHO-pgsA745 and CHO-pgsD677 this same condition resulted in enhancement of infection (p,0.01 in multiple
Student’s t-test with Bonferroni correction). Data are presented as percentages GFP-positive cells (means 6 SD of triplicates). A representative
experiment out of three is shown.
doi:10.1371/journal.ppat.1001049.g006
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observed interactions between RSV and pneumococci [18,19]. We
speculate that carriage of respiratory bacteria in the upper or
lower respiratory tract could facilitate binding of RSV to their
target cells and thus play a role in the pathogenesis of severe RSV
bronchiolitis. This would be a possible explanation for the fact that
polyvalent pneumococcal vaccination has been associated with
reduced RSV hospitalization rates [13]. Our results indicate that
APCs are normally relatively resistant to RSV infection. However,
lipopeptides such as Pam3CSK4 strongly enhanced rgRSV
infection of these cells. Increased binding of RSV to and infection
of APCs may boost immune activation and might as such be
involved in pulmonary disease during RSV and bacterial co-
infections.
Pam3CSK4 has been evaluated in several studies as a potential
adjuvant for peptide vaccines [50–52]. Interestingly, our data
suggest that the lipopeptide could also be considered as a potential
adjuvant for live-attenuated virus vaccines. Development of a live-
attenuated RSV vaccine has been hampered by difficulties in
finding a proper balance between attenuation and immunogenic-
ity of candidate vaccine viruses [53]. Pam3CSK4 has the potential
to enhance binding of a live-attenuated RSV vaccine administered
intra-nasally, while also stimulating innate immune responses
through TLR1/2 interactions. However, as RSV vaccines will
need to be given to very young infants, this latter property may be
undesired. Alternatively, the non-TLR agonists Pam-Cys-SK4 or
PHCSK4 could be considered as adjuvants, resulting in enhanced
binding of an over-attenuated live-attenuated RSV vaccine
without resulting in immune stimulation. Currently, we are
performing studies in animal models to test this hypothesis.
In conclusion, we have shown that Pam3CSK4 and at least two
structurally related cationic lipopeptides can enhance infections
with RSV, HIV-1, human metapneumovirus and measles virus. In
contrast to our initial hypothesis, this effect proved to be
independent of TLR1/2 signaling but was mediated by enhancing
binding of the viruses to their target cells.
Materials and Methods
Ethics statement
Human BAL cells were collected from patients suspected for
pulmonary sarcoidosis in the framework of another study [54].
After written informed consent patients underwent fibre-optic
bronchoscopy. The protocol was approved by the Medical Ethical
Committee of the Erasmus University, Rotterdam.
Cells
A549 cells (human pneumocyte type II carcinoma cells, ATCC
CCL-185) and Epstein-Barr virus-transformed human B-LCL [55]
GR were cultured in RPMI-1640 medium (Lonza) supplemented
with L-glutamine, penicillin, streptomycin (Lonza) and 10% fetal
bovine serum (FBS, Sigma-Aldrich). HEp-2 cells (human naso-
pharyngeal carcinoma cells, ATCC CCL-23) were cultured in
Dulbecco’s Modified Eagle Medium (Lonza) supplemented with
L-glutamine, penicillin, streptomycin and 10% FBS. Monocyte-
derived immature DCs were cultured as described [56]. In short,
human peripheral blood monocytes were isolated from buffy coats
(provided by Sanquin Blood Bank South West Region, Rotter-
dam) by density centrifugation, followed by selection of CD14
+
cells using magnetic beads (MACS, Miltenyi Biotec GmbH).
Purified monocytes were cultured in RPMI-1640 medium
supplemented with L-glutamine, penicillin, streptomycin and
10% FBS and differentiated into immature DCs in the presence
of IL-4 and GM-CSF (500 and 800 U/ml, respectively; Schering-
Plough). Human broncho-alveolar (BAL) cells were cultured in
RPMI-1640 supplemented with antibiotics and 10% FBS. NHBE
cells (Clonetics) were used undifferentiated. Cells were cultured in
30 mg/ml type I collagen- (Nutacon) and 10 mg/ml fibronectin-,
(Sigma-Aldrich) coated (culture flasks or flat-bottom 96-well plates
(Corning) in bronchial epithelial cell basal medium (Clonetics)
supplemented with penicillin and streptomycin. CHO K-1 cells
(ATCC CCL-61), CHO pgsA-745 cells (ATCC CRL-2242) and
CHO pgsD-677 cells (ATCC CRL-2244) were cultured in Ham’s
F12K medium supplemented with 10% FBS, penicillin and
streptomycin. Jurkat T cells expressing CCR5 were previously
described [28] and cultured in RPMI-1640 medium (Lonza)
supplemented with 4500 mg/L glucose, 110 mg/l sodium pyru-
vate, 4 mM L-glutamine, 10% FBS, penicillin and streptomycin.
Viruses
To generate HIV-1-GFP, 293T cells were transfected with the
NL4.3-eGFP-BaL proviral plasmid (4 mg; generously provided by
C. Aiken, Vanderbilt University, Tennessee, USA). After 3 days
the NL4.3-eGFP-BaL virus was harvested and titrated using the
indicator cells TZM-blue (contributed by John C. Kappes,
Xiaoyun Wu [both at University of Alabama, Birmingham,
Alabama, USA], and Tranzyme Inc. through the NIH AIDS
Research and Reference Reagent Program). HMPV-EGFP (strain
00-1) was grown as described previously [57] and had a titer of
6.3610
6 TCID50/ml. Recombinant pathogenic and attenuated
MV expressing EGFP were grown as described previously [58,59].
The titers of recombinant pathogenic and attenuated MV were
1610
6 TCID50/ml and 6.3610
4 TCID50/ml, respectively. rgRSV
is a recombinant virus based on RSV strain A2, which was a kind
gift of Dr. M.E. Peeples and Dr. P.L. Collins. The construction
and rescue of rgRSV has been described in detail elsewhere [32].
Briefly, GFP was inserted as the first, promoter-proximal gene in a
full-length cDNA of the RSV A2 antigenomic RNA. As a
consequence rgRSV-infected cells express GFP upon infection.
rgRSV has been described to have the same growth kinetics and
virological characteristics as the RSV A2 strain [32,40]. rgRSV
was grown and titrated on HEp-2 cells and aliquots were stored at
280uC until use. The titer of the virus used in these studies was
1610
7 TCID50/ml. Other (non recombinant) RSV strains used
were the RSV subgroup A strains RSV Long (ATCC VR-26) and
RSV A2 (ATCC VR1302), the RSV subgroup B strain 9320
(ATCC VR955) and three wild-type RSV isolates from our
hospital archives, which were used at passage 2 in HEp-2 cells.
Lipopeptides
Pam-Cys-SK4, PamDhcSK4, PamSK4, Pam2CSK4,
Pam3CSE4, Pam3CSH4, Pam3CSK2, Pam3CSK4, Pam3CSK5,
Pam3CSP4, Pam3CSR4, PHCSK4, Pam3CSK4-CF and CSK4-
CF were synthesized by EMC microcollections, Germany (see
Figure S1 for molecular structures). Stocks were prepared in
distilled water at 1 mg/ml.
TLR agonist experiment
A549, HEp-2, NHBE cells (2610
4 cells per well), monocyte-
derived immature DCs, BAL cells or B-LCL (5610
4 cells per well in
96-well flat-bottom plates) were incubated with different TLR
agonists (InvivoGen) for 6 hours as described previously [28].
Pam3CSK4, Pam2CSK4, purified LTA-SA, peptidoglycan from S.
aureus (PGN-SA), lipopolysaccharide from E. coli (LPS) were
incubated at final concentrations of 10 mg/ml and a synthetic di-
acylated lipoprotein (FSL-1) and flagillin from B. subtilis at final
concentrations of 1 mg/ml. Heat killed L. monocytogenes (HKLM) was
used at a concentration of 1610
8/ml. After the 6 hour incubation,
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4 TCID50 per well for
A549, HEp-2 and NHBE cells, 5610
4 TCID50 per well for
immature DCs and 1610
5 TCID50 per well for BAL cells and B-
LCL). 24 h post infection the cells were trypsinized (only for
adherent cells) and percentages of GFP-positive cells were
determined by flow cytometry (FACS Canto II, Becton-Dickinson).
Experiments with lipopeptides only
5610
4 B-LCL were seeded in 96-well flat-bottom plates (V-
bottom plates, if the cells were washed during the experiment).
Unless stated otherwise, cells were pre-incubated with lipopeptides
for 30 min before rgRSV was added (1610
5 TCID50), hereafter
referred to as pre-incubation on cells. In some experiments, virus
was pre-incubated with Pam3CSK4 for 30 min before addition to
the cells, hereafter referred to as pre-incubation of virus. In these
experiments, the virus was pre-incubated in a small volume and
subsequently diluted at least 1:10 before addition to the cells. 20–
24 h post infection the percentages of GFP-positive cells were
determined by flow cytometry (FACS Canto II, Becton-Dickinson).
MyD88 experiment/TLR1/2 blocking
5610
4 B-LCL cells were plated in 96-well v-bottom plates. The
cells were either pre-incubated with the myeloid differentiating
factor 88 (MyD88) homodimerization inhibitory peptide (100 mM,
Imgenex, USA) for 24 h or with polyclonal blocking antibodies to
TLR1, TLR2, TLR4 or the combination of TLR1 and TLR2
(20 mg/ml, InvivoGen, USA) for 30 minutes. The cells were then
incubated with Pam3CSK4 and subsequently infected with rgRSV
(1610
5 TCID50). 20–24 h post infection the percentages of GFP-
positive cells were determined by flow cytometry.
RSV binding assays
To assess lipopeptide-mediated enhancement of RSV binding to
cells, B-LCL (3610
4) were incubated with rgRSV (2.2610
5
TCID50) that had been pre-incubated (30 minutes, 37u) with
lipopeptide (10 mg/ml). After 15 minutes at 37uC, cells were
washed and incubated with FITC-labeled anti-RSV or anti-
influenza-B as a control (Imagen immunofluorescence tests,
OXOID, diluted 1:10 in complete RPMI).
To assess binding of lipopeptides to RSV, lipopeptides were
coated on high-binding 96-wells flat-bottom ELISA plates at a
concentration of 300 ng/well in acetate buffer (pH 4.6) for two
hours (37uC), after which free binding sites were blocked for one
hour (37uC) with DMEM supplemented with 10% FBS. After
washing, wells were incubated with RSV-A2 or with measles virus
strain Edmonston as a control (both 10
6 TCID50 per well) as
control (1 hr, 37uC), followed by washing and addition of anti-
RSV antibody (NIH clone 1107). ELISA plates were subsequently
stained with goat-anti-mouse peroxidase and TMB as a substrate,
and extinctions were determined at 450 nm.
To assess binding of lipopeptides to cells, B-LCL were incubated
with different concentrations of carboxyfluoresceine-labeled Pam-
3CSK4 (Pam3CSK4-CF, Mw 2094) or CSK4 (CSK4-CF, Mw 1079)
for 30 minutes at 4uCo r3 7 uC. Subsequently, cells were washed twice
and fluorescence was measured by flow cytometry. Results are shown
as the geometric mean fluorescence (mean 6 SD of triplicates).
Polyanion experiments
Polyanion reagents (heparin, dextran sulfate, and chondroitin
sulfate) were obtained from Sigma-Aldrich. Oversulfated heparin,
de-O-sulfated heparin and oversulfated chondroitin sulfate were
obtained from Neoparin. The polyanions were stored in PBS at a
concentration of 30 mg/ml at 220uC. 5610
4 B-LCL were plated
in 96-well v-bottom plates. The cells were pre-incubated with
different lipopeptides for 15 minutes at 37uC and subsequently
incubated for 15 minutes with the indicated polyanions (30 mg/
ml). The cells were washed three times and infected with rgRSV
(1610
5 TCID50).
Enhancement studies with HIV-1, HMPV and MV
5610
4 Jurkat-CCR5 cells were plated in 96-well u-bottom
plates and pre-incubated with different lipopeptides and subse-
quently inoculated with NL4.3-eGFP-BaL at different concentra-
tions in the presence or absence of the indicated lipopeptides (all at
10 mg/ml). Two days post infection the cells were fixed and
percentages of EGFP-positive cells were determined by flow
cytometry. The other viruses were tested in B-LCL, using a single
MOI and a concentration range of lipopeptide as described above,
and determining percentages GFP-positive cells 20–24 hours post
infection.
Statistical analysis
All experiments were performed at least three times using
triplicate measurements, except for the ELISA experiment with
lipopeptides,whichhadduplicatemeasurements.Dataareexpressed
as means 6 standard deviations. Differences between two groups
(treatment and control) were analyzed with Student’s t-test, using
Bonferroni’s correction to correct for multiple comparisons. When
comparing multiple treatment groups to the same control,
differences were compared using 1-Way ANOVA with Dunnett’s
Correction for multiple comparisons. A two-sided (uncorrected) p-
value,0.05 was considered statistically significant. Methods for
specific statistical comparisons are given in the figure legends.
Supporting Information
Figure S1 Molecular structures of (lipo)peptides used in this
study.
Found at: doi:10.1371/journal.ppat.1001049.s001 (0.32 MB TIF)
Figure S2 Binding of measles virus (MV) pre-incubated with
different lipopeptides to Vero cells
Found at: doi:10.1371/journal.ppat.1001049.s002 (1.19 MB TIF)
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